Aapro, Matti S.
Chaplin, Stephen
Cornes, Paul
Howe, Sebastian
Link, Hartmut
Koptelova, Natalia
Mehl, Andrea
Di Palma, Mario
Schroader, Bridgette Kanz
Terkola, Robert
Article History
Received: 30 January 2023
Accepted: 6 September 2023
First Online: 20 September 2023
Declarations
:
: No ethics approval was required for this work as it did not involve patient-specific information.
: SC and BKS are employees of Xcenda. SH, AM, and NK are employees of Sandoz. RT and MA have no competing interests to disclose. HL reports financial interests via advisory board involvement in the following: Apogepha, G1 Therapeutics, Hogg Robinson Germany, Lindis Blood Care, Pharmacosmos, Servier Deutschland GmbH, SIGAL SMS GmbH, Takeda, and Teva; expert testimony for Samsung Bioepis and Ethics Committee at the Rhineland-Palatinate Medical Association; invited speaker for Teva and Vision Plus Mailand; and ownership interest, research grants, licencing fees, coordinating PI, and steering committee member for Onkodin GmbH, AMGEN and Pharmacosmos, Viatris, and Teva-Xcenda, respectively. PC declares honoraria or support for attending meetings from Accord Healthcare, Amgen, Astro Pharma, European Association for Hospital Pharmacists, European Commission, Medicines for Europe/European Generics Association, Medscape, Mylan, Napp, Pfizer/Hospira, Sandoz, Teva and Viatris. MP reports clinical research projects with Bayer, Sandoz, Pierre Fabre, Fresenius, Astellas, Janssen, and Sanofi; Speakers’ bureau with Amgen, KyowaKirin, MSD, and Mundipharma; Honoraria from Novartis and AstraZeneca; travel and accommodations and expenses from Pfizer and Novartis.